CVS Health Corporation reported on Thursday that its revenue in the second quarter of fiscal 2025 stood at $98.9 billion, rising by 8.4% compared to the same period in the previous year and exceeding analysts' estimates. The net income declined by 42.7% on an annual basis to $ billion in the reported quarter, while its diluted earnings per share (EPS) dipped by 43.3% year-on-year to $0.80.
The company also raised its full-year 2025 outlook for the adjusted EPS to now land in the range between $6.30 and $6.40, and for the cash flow from operations to reach at least $7.5 billion.
"Our strong performance demonstrates the continued focus we have on operational and financial improvement across our businesses, led by a significant and durable recovery at Aetna, strong retention at CVS Caremark and growth and momentum at CVS Pharmacy," CEO David Joyner said.
CVS stock rose by 8.67% during premarket trading after the report's release to sell for $67.70 apiece at 6:48 am ET.
